Department of Justice August 2023 – Federal Register Recent Federal Regulation Documents

Agency Information Collection Activities; Proposed eCollection eComments Requested; 2023 Law Enforcement Administrative and Management Statistics (LEMAS) Supplement Survey-Post-Academy Training and Officer Wellness (PATOW)
Document Number: 2023-17238
Type: Notice
Date: 2023-08-11
Agency: Department of Justice
The Bureau of Justice Statistics, Office of Justice Programs, Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection was previously published in the Federal Register on May 16, 2023, allowing a 60-day comment period.
Bulk Manufacturer of Controlled Substances Application: Continuus Pharmaceuticals
Document Number: 2023-17136
Type: Notice
Date: 2023-08-10
Agency: Drug Enforcement Administration, Department of Justice
Continuus Pharmaceuticals has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Importer of Controlled Substances Application: Chattem Chemicals
Document Number: 2023-17139
Type: Notice
Date: 2023-08-10
Agency: Drug Enforcement Administration, Department of Justice
Chattem Chemicals has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Importer of Controlled Substances Application: Caligor Coghlan Pharma Services
Document Number: 2023-17138
Type: Notice
Date: 2023-08-10
Agency: Drug Enforcement Administration, Department of Justice
Caligor Coghlan Pharma Services has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Importer of Controlled Substances Application: Cambrex Charles City
Document Number: 2023-17038
Type: Notice
Date: 2023-08-09
Agency: Drug Enforcement Administration, Department of Justice
Cambrex Charles City has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Importer of Controlled Substances Application: Cerilliant Corporation
Document Number: 2023-17037
Type: Notice
Date: 2023-08-09
Agency: Drug Enforcement Administration, Department of Justice
Cerilliant Corporation has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Bulk Manufacturer of Controlled Substances Application: Chemtos, LLC
Document Number: 2023-17036
Type: Notice
Date: 2023-08-09
Agency: Drug Enforcement Administration, Department of Justice
Chemtos, LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Importer of Controlled Substances Application: Galephar Pharmaceutical Research, Inc.
Document Number: 2023-17035
Type: Notice
Date: 2023-08-09
Agency: Drug Enforcement Administration, Department of Justice
Galephar Pharmaceutical Research, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
Document Number: 2023-17034
Type: Notice
Date: 2023-08-09
Agency: Drug Enforcement Administration, Department of Justice
ANI Pharmaceuticals Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.
Bulk Manufacturer of Controlled Substances Application: Cambrex High Point, Inc.
Document Number: 2023-17030
Type: Notice
Date: 2023-08-09
Agency: Drug Enforcement Administration, Department of Justice
Cambrex High Point, Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
Agency Information Collection Activities; Proposed eCollection eComments Requested; Revision of a Previously Approved Collection; Notice of Entry of Appearance as Attorney or Representative Before the Board of Immigration Appeals
Document Number: 2023-17028
Type: Notice
Date: 2023-08-09
Agency: Department of Justice
The Executive Office for Immigration Review (EOIR), Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC
Document Number: 2023-17021
Type: Notice
Date: 2023-08-09
Agency: Drug Enforcement Administration, Department of Justice
Catalent Pharma Solutions, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Agency Information Collection Activities; Proposed eCollection eComments Requested; New Collection; Crime Victims' Rights Act Complaint Form
Document Number: 2023-14886
Type: Notice
Date: 2023-08-08
Agency: Department of Justice
The Office of the Victims' Rights Ombuds, Executive Office for United States Attorneys, Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
Dispensing of Narcotic Drugs To Relieve Acute Withdrawal Symptoms of Opioid Use Disorder
Document Number: 2023-16892
Type: Rule
Date: 2023-08-08
Agency: Drug Enforcement Administration, Department of Justice
The Drug Enforcement Administration (DEA) is revising existing regulations to expand access to medications for the treatment of opioid use disorder pursuant to the Easy Medication Access and Treatment for Opioid Addiction Act (the Act). The Act directed DEA to revise its regulation to allow practitioners to dispense not more than a three-day supply of narcotic drugs to one person or for one person's use at one time for the purpose of initiating maintenance treatment or detoxification treatment (or both).
Agency Information Collection Activities; Proposed eCollection eComments Requested; Revision of a Previously Approved Collection; OJP Solicitation Template
Document Number: 2023-16872
Type: Notice
Date: 2023-08-08
Agency: Department of Justice
The Office of Justice Programs (OJP), Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
Practice of Telemedicine: Listening Sessions
Document Number: 2023-16889
Type: Notice
Date: 2023-08-07
Agency: Drug Enforcement Administration, Department of Justice
The Drug Enforcement Administration (DEA) is conducting public listening sessions to receive additional input concerning the practice of telemedicine with regards to controlled substances and potential safeguards that could effectively prevent and detect diversion of controlled substances prescribed via telemedicine. Specifically, DEA is inviting all interested persons, including medical practitioners, patients, pharmacy professionals, industry members, law enforcement, and other third parties to express their views at the listening sessions concerning the advisability of permitting telemedicine prescribing of certain controlled substances without any in-person medical evaluation at all, the availability and types of data that would be useful in detecting diversion of controlled substances via telemedicine that are either already reported or could be reported, and specific additional safeguards that could be placed around the prescribing of schedule II controlled substances via telemedicine.
Nondiscrimination on the Basis of Disability; Accessibility of Web Information and Services of State and Local Government Entities
Document Number: 2023-15823
Type: Proposed Rule
Date: 2023-08-04
Agency: Department of Justice
The Department of Justice (``Department'') is proposing to revise the regulation implementing title II of the Americans with Disabilities Act (``ADA'') in order to establish specific requirements, including the adoption of specific technical standards, for making accessible the services, programs, and activities offered by State and local Government entities to the public through the web and mobile apps.
Agency Information Collection Activities; Proposed eCollection eComments Requested; Revision of a Previously Approved Collection; Investigator Quality Survey-ATF Form 8620.7
Document Number: 2023-16547
Type: Notice
Date: 2023-08-03
Agency: Department of Justice
The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
Notice of Extension of Public Comment Period
Document Number: 2023-16493
Type: Notice
Date: 2023-08-03
Agency: Department of Justice
Agency Information Collection Activities; Proposed eCollection eComments Requested; New Collection; Crime Victims' Rights Act Complaint Form
Document Number: 2023-16432
Type: Notice
Date: 2023-08-02
Agency: Department of Justice
The Office of the Victims' Rights Ombuds, Executive Office for United States Attorneys (EOUSA), Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension of a Previously Approved Collection; Statement of Claim for Filing of Claims in the Guam Claims Program Pursuant to the Guam World War II Loyalty Recognition Act
Document Number: 2023-16291
Type: Notice
Date: 2023-08-01
Agency: Department of Justice
The U.S. Marshals Service (USMS), Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension of a Previously Approved Collection; Procurement Collusion Strike Force Complaint Form
Document Number: 2023-16290
Type: Notice
Date: 2023-08-01
Agency: Department of Justice
The U.S. Marshals Service (USMS), Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
Agency Information Collection Activities; Proposed eCollection eComments Requested; New Collection; Supervised Visitation and Safe Exchange Guiding Principles Reflection Survey for Past and Current Grantees
Document Number: 2023-16289
Type: Notice
Date: 2023-08-01
Agency: Department of Justice
The Office on Violence Against Women (OVW), Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
Implementation of the Designer Anabolic Steroid Control Act of 2014
Document Number: 2023-15747
Type: Rule
Date: 2023-08-01
Agency: Drug Enforcement Administration, Department of Justice
On December 18, 2014, the Designer Anabolic Steroid Control Act of 2014 (DASCA) became law. The Act amended the Controlled Substances Act to revise and add specified substances to the definition of ``anabolic steroid.'' The Act provided a new mechanism for temporary and permanent scheduling of anabolic steroids, and added specific labeling requirements for products containing anabolic steroids. The Drug Enforcement Administration (DEA) is publishing this rule to amend and reorganize its regulations to make them consistent with DASCA regarding the updated definition, specific substances, criteria and timeframes applicable to temporary and permanent scheduling of anabolic steroids, and labeling requirements.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.